Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CPA1 | P15085 | 7/20 | 0.49 |
| ▸ | CPA3 | P15088 | 3/20 | 0.49 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.49 |
| ▸ | CPB1 | P15086 | 1/20 | 0.49 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.49 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.45 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.45 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.45 |
| ▸ | MME | P08473 | 2/20 | 0.43 |
| ▸ | LTA4H | P09960 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21797574 | 0.95 | CYP1A2 (0.49) | CYP1A2CPA1CPA3FOLH1CPB1 | |
| SCHEMBL8710569 | 0.87 | FOLH1 (0.43) | CYP1A2FOLH1 | |
| SCHEMBL16798256 | 0.87 | PPARA (0.39) | CYP1A2CPA1MME | |
| SCHEMBL16798242 | 0.87 | KMT2A (0.44) | CYP1A2MME | |
| SCHEMBL7417051 | 0.86 | BTN3A1 (0.43) | CYP1A2MMELTA4H | |
| SCHEMBL16798290 | 0.86 | CTSL (0.42) | CYP1A2FOLH1 | |
| SCHEMBL16798289 | 0.85 | PPARA (0.47) | CYP1A2FOLH1 | |
| SCHEMBL31694087 | 0.81 | RIPK1 (0.37) | CPA1MME | |
| SCHEMBL3428431 | 0.80 | ADRB2 (0.40) | — | |
| SCHEMBL3428434 | 0.80 | ADRB2 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11376260-B2 | Serine/threonine kinase inhibitors | GENENTECH, INC. (US) | 2022-07-05 | — | — | US | disclosed |
| US-20210106593-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2021-04-15 | — | — | US | disclosed |
| US-10842799-B2 | Serine/threonine kinase inhibitors | GENENTECH, INC. (US) | 2020-11-24 | — | — | US | disclosed |
| US-20200078371-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2020-03-12 | — | — | US | disclosed |
| US-20190192534-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2019-06-27 | — | — | US | disclosed |
| US-10278975-B2 | Serine/threonine kinase inhibitors | GENENTECH, INC. (US) | 2019-05-07 | — | — | US | disclosed |
| EP-3077401-B1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH INC (US) | 2018-04-18 | — | — | EP | disclosed |
| US-9867833-B2 | Serine/threonine kinase inhibitors | GENENTECH, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-20180000833-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2018-01-04 | — | — | US | disclosed |
| EP-3077401-A1 | SERINE/THREONINE KINASE INHIBITORS | Genentech, Inc. (US) | 2016-10-12 | — | — | EP | disclosed |
| EP-0686155-B1 | XANTHINE DERIVATIVES AS ADENOSINE A1 RECEPTOR ANTAGONISTS | MERRELL PHARMA INC (US) | 1998-07-29 | — | — | EP | disclosed |
| EP-0449175-B1 | Selective adenosine receptor agents | MERRELL PHARMA INC (US) | 1997-07-30 | — | — | EP | disclosed |
| EP-0686155-A1 | XANTHINE DERIVATIVES AS ADENOSINE A1 RECEPTOR ANTAGONISTS | MERRELL PHARMACEUTICALS INC. (US) | 1995-12-13 | — | — | EP | disclosed |
| US-5438118-A | Peptide mimics having constrained peptide backbone | SMITHKLINE BEECHMAN CORP. (US) | 1995-08-01 | — | — | US | disclosed |
| WO-1994019349-A1 | XANTHINE DERIVATIVES AS ADENOSINE A1 RECEPTOR ANTAGONISTS | MERRELL DOW PHARMACEUTICALS INC. (US) | 1994-09-01 | — | — | WO | disclosed |
| EP-0559793-A4 | — | — | 1994-04-27 | — | — | EP | disclosed |
| EP-0559793-A1 | HIV PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-09-15 | — | — | EP | disclosed |
| WO-1992009297-A1 | HIV PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1992-06-11 | — | — | WO | disclosed |
| EP-0449175-A2 | Selective adenosine receptor agents | MERRELL PHARMACEUTICALS INC. (US) | 1991-10-02 | — | — | EP | disclosed |
| US-5047534-A | Xanthine derivatives; hyupotensive agents, cardiotonic agents | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11376260-B2 | Serine/threonine kinase inhibitors | MAP3K1, MAP3K4, MAP4K2 | CYP1A2 3796/4885CPA1 4496/4885CPA3 4414/4885 |
| US-10842799-B2 | Serine/threonine kinase inhibitors | MAP3K1, MAP3K4, MAP4K2 | CYP1A2 3796/4885CPA1 4496/4885CPA3 4414/4885 |
| US-20180000833-A1 | SERINE/THREONINE KINASE INHIBITORS | MAP3K1, MAP3K4, MAP4K2 | CYP1A2 3796/4885CPA1 4496/4885CPA3 4414/4885 |
| US-10278975-B2 | Serine/threonine kinase inhibitors | MAP3K1, MAP3K4, MAP4K2 | CYP1A2 3796/4885CPA1 4496/4885CPA3 4414/4885 |
| US-20190192534-A1 | SERINE/THREONINE KINASE INHIBITORS | MAP3K1, MAP3K4, MAP4K2 | CYP1A2 3796/4885CPA1 4496/4885CPA3 4414/4885 |
| US-20210106593-A1 | SERINE/THREONINE KINASE INHIBITORS | MAP3K1, MAP3K4, MAP4K2 | CYP1A2 3796/4885CPA1 4496/4885CPA3 4414/4885 |
| US-20200078371-A1 | SERINE/THREONINE KINASE INHIBITORS | MAP3K1, MAP3K4, MAP4K2 | CYP1A2 3796/4885CPA1 4496/4885CPA3 4414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.